Eisai and Biogen Advance LEQEMBI Access in Canada
TOKYO and CAMBRIDGE, Mass., August 31, 2026 Eisai and Biogen announced that Canada’s Drug Agency (CDA-AMC) has issued a...
drug reimbursement
Advertisement
Takeda Canada Secures REVESTIVE Reimbursement in BC
TORONTO, ON, Canada – May 5, 2026 Takeda Canada Inc. has announced that REVESTIVE® (teduglutide for injection) will now...
Hemostemix Advances ACP-01 With FDA Pre-IND Milestone
CALGARY, Alberta, Dec. 10, 2025 — Hemostemix Inc., a leader in autologous stem cell therapeutics, announced two pivotal corporate...
Scemblix® Gets Priority Access Under Ontario’s FAST Program
MONTREAL, QC, Dec. 10, 2025 — Scemblix® (asciminib) has become one of the first therapies prioritized for public reimbursement...
Advertisement
